CClinicalTrials.gg
Not yet recruitingNCT07765797ProChangeUpdated Aug 14, 2026

Development and Validation of a Scale of Propensity for Change in Chronic Disease Prevention

An observational study in Atheroscleroses and Geriatric, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by University Hospital, Toulouse · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
290
Ages
45 Years and older
Sex
All
01

Study summary

Modifiable risk factors are estimated to account for 70% of cardiovascular diseases, 40% of Alzheimer's-type dementias, and 50% of type 2 diabetes cases. Numerous trials have evaluated interventions aimed at modifying these risk factors, whether through the promotion of healthy lifestyle choices (diet, physical activity, etc.) or specific activities (cognitive training, etc.). However, these trials have yielded inconsistent or modest results, potentially due to a failure to adopt the recommended lifestyle changes. To better tailor prevention interventions, it is therefore essential to have scales available that measure the barriers to and facilitators of lifestyle change.

The aim of this study is to develop and validate a Patient-Reported Outcome Measure (PROM) to assess the barriers to and facilitators of change following participation in a prevention program. The scale will be structured into three sub-scales (capability, opportunity, and motivation), administered one month after the prevention activity, and will distinguish between the adoption of new habits and the abandonment of existing ones.

02

Conditions studied

  • Atheroscleroses
  • Geriatric

Browse trials for

Keywords

  • prevention
  • gériatrics
  • risk factors
03

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients benefiting from a personalized prevention program in the context of geriatrics or cardiovascular diseases.

Inclusion criteria

  • Participant receiving a personalized prevention intervention through the frailty assessment day-hospital program, the Atherosclerosis Detection and Prevention Center (CDPA), or the Salutance program,
  • Participant who has received prevention advice aimed at improving their health in at least one of the following two areas: nutrition or physical activity,
  • Participant aged 45 or older (we are targeting a middle-aged to older population, as this group is the primary target for cardiovascular prevention initiatives and efforts to prevent pathological aging),

Exclusion criteria

Exclusion Criteria:

  • Participant unable to improve their lifestyle, according to the scales used in the study (participant with a maximum score on the ONAPS-PAQ scale and the food frequency score),
  • Participant without a postal or email address,
  • Participant with a life expectancy of less than 5 years.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
290 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients benefiting from a personalized prevention initiative

    patients benefiting from a personalized prevention initiative aimed at improving nutritional or physical health

    Other: Scale development phase · Other: Beta testing phase · Other: Validation phase

Interventions

  • OtherScale development phase

    Questionnaire administered to patients to develop the scale's items and group them into subscales.

  • OtherBeta testing phase

    The scale will be administered to the patient in the form of a questionnaire for the testing phase.

  • OtherValidation phase

    The scale will be administered to patients in the form of questionnaires for the validation phase.

05

What researchers measure

Primary outcomes

  1. Development of the Prochange scale assessing barriers to and facilitators of lifestyle changes for the adoption of non-pharmacological strategies in the field of prevention.

    Development of a scale based on COSMIN criteria (COnsensus-based Standards for the selection of health Measurement INstruments), consisting of three subscales of 10 questions each.

    Time frame: 3 months after the inclusion

Secondary outcomes

  1. Measurement of the area under the curve of the Prochange scale for the prediction of an improvement in lifestyle at 3 months after the initiation of a preventive action

    Time frame: 3 months after the inclusion

  2. Comparison of the performance of the ProChange scale with that of pre-existing scales in predicting lifestyle change three months after the initiation of a prevention intervention.

    Time frame: 3 months after the inclusion

  3. Evaluation of the correlation between the score obtained on the ProChange scale one month after the prevention intervention and the extent of lifestyle modification three months after the initiation of the prevention intervention

    Time frame: 3 months after the inclusion

  4. Comparison of the ProChange scale with pre-existing scales

    Comparison of the ProChange scale with pre-existing scales in terms of the correlation between the score obtained on the scale one month after the prevention intervention and the extent of lifestyle change three months after the initiation of the prevention intervention.

    Time frame: 3 months after the inclusion

06

Study locations

1 site
  • Service d'Epidémiologie Clinique et de Santé Publique CHU de Toulouse, Pôle Santé Publique et Médecine Sociale Faculté de Médecine, 37 allées Jules Guesde
    Toulouse, Oui 31000, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07765797
Lead sponsor
University Hospital, Toulouse
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Jason SHOURICK, MD
Contact
shourick.j@chu-toulouse.fr
05 61 14 56 23 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion